The march of molecular genomics is progressing from the laboratory to the clinic. Within the pharmaceutical industry, applications of clinical genomics promises to enhance the discovery of drug response markers, reduce the size and expense of clinical drug trials, and provide tools for addressing regulatory approval issues. All agree that applying biological knowledge through prospective genotyping early in clinical trials is necessary, but putting the theory into practice remains a bottleneck. Cambridge Healthtech Institute’s Translating Genomic Knowledge: Biological Discovery to Clinical Utility expounds the driving factors that are encouraging pharmacogenetic strategy development in the pharmaceutical industry.

February 25-27, 2009
San Francisco, CA
Moscone North Convention Center

As the need for new technologies, improved strategies and competitive intelligence becomes ever more acute, CHI’s flagship event, the MOLECULAR MEDICINE TRI-CONFERENCE provides the breadth and depth of information critical to your organization’s success. The 2009 event includes ELEVEN parallel tracks that provide compelling and in-depth insight into the future of molecular medicine. These tracks add up to an indispensable conference for professionals grappling with the challenges of delivering 21st century medicine.